Sickle Cell Anemia Testing Screening Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

The sickle cell anemia testing and screening market encompasses diagnostic technologies used to detect the inherited hemoglobin disorder, ranging from traditional hemoglobin electrophoresis to modern molecular genetic assays and point-of-care lateral flow tests. Valued at roughly $0.48 to $0.49 billion in 2025, the market is entering a sustained growth phase as healthcare systems in high-burden regions formalize screening protocols and as diagnostic accuracy improves through automation and digital analysis tools.

• •Estimated market size of approximately $0.49 billion in 2025, rising to roughly $0.54 billion in 2026
• •Long-term projections place market value between $1.52 billion and $1.58 billion by 2035
• •Technology portfolio includes hemoglobin electrophoresis, isoelectric focusing, HPLC, DNA-based assays, and rapid immunoassay-based screening platforms

The primary engine of market growth is the rising global burden of sickle cell disease, compounded by the fact that approximately 75% of affected births occur in sub-Saharan Africa where screening coverage has historically been limited. Government-mandated newborn screening programs, particularly in North America and parts of Europe, have created stable baseline demand, while parallel initiatives in India, the Middle East, and the Caribbean are opening new market corridors. Technological innovation is further accelerating adoption by enabling faster, more affordable, and more portable testing that is suitable for low-resource environments.

• •Disease prevalence rising toward 400,000 affected newborns per year globally by 2050, with highest concentrations in sub-Saharan Africa, India, and the Middle East
• •Expanding newborn screening mandates and population-level carrier screening policies in both developed and emerging-market countries
• •Advances in molecular diagnostics, point-of-care platforms, and AI-assisted microscopy are reducing cost and complexity while improving diagnostic accuracy

The market is typically segmented by test type, end-use setting, and geography. North America held the largest regional share, estimated at around 40% of the global market in 2025, supported by established newborn screening infrastructure, favorable reimbursement frameworks, and high disease awareness. Asia-Pacific is anticipated to be the fastest-expanding regional market, driven by large at-risk populations, improving healthcare access, and increasing government prioritization of genetic disease screening.

• •North America dominated with an estimated 40% market share in 2025, anchored by comprehensive newborn screening laws and well-developed laboratory infrastructure
• •Asia-Pacific projected to register the highest compound annual growth rate over the forecast period, reflecting rising disease burden and expanding screening programs
• •Sub-Saharan Africa represents the largest unmet-need opportunity, given high disease prevalence and historically low screening penetration, with growing international health program support

Who are the notable companies in the industry?

The competitive structure of the sickle cell testing market is moderately fragmented, with a mix of large diversified in vitro diagnostic corporations and smaller specialty firms focused on hematology and genetic screening technologies. Integrated producers with broad diagnostic portfolios compete alongside more focused players that differentiate through proprietary molecular or immunodiagnostic platforms. Capacity and innovation concentration is highest in North America, Western Europe, and major Asian manufacturing hubs, while the technology base spans both established methods such as electrophoresis and chromatography and newer routes including PCR-based and isothermal nucleic acid amplification.

• •Moderately fragmented competitive structure with a combination of broad-line diagnostic conglomerates and niche specialty producers
• •Technology routes include traditional electrophoresis and HPLC methods alongside emerging molecular, isothermal amplification, immunoassay, and AI-enhanced digital microscopy platforms
• •Manufacturing and R&D capacity is concentrated primarily in North America, Europe, and key Asian industrial centers, with emerging-market participation growing through technology transfer and regional partnerships

What are the recent trends and outlook?

Looking ahead, the market is expected to sustain double-digit growth through 2035, supported by converging trends in expanded screening policy, affordable portable diagnostics, and the broader ecosystem of sickle cell disease management that now includes pharmacological and gene-based therapies. The approval of gene therapy treatments has reinforced demand for companion genetic testing and confirmed carrier status, adding a new dimension to test utilization. Over the longer term, widespread adoption of low-cost point-of-care solutions and integration of screening into primary care and community health settings in high-burden regions will likely determine how fully the market realizes its growth potential.

• •Convergence of gene therapy approvals and associated companion diagnostic requirements is creating new demand for high-resolution genetic testing
• •Point-of-care and decentralized testing models are gaining momentum as a strategy to extend screening reach into rural and resource-constrained populations
• •Sustained public-sector investment and international health initiatives targeting neglected genetic diseases are expected to underpin market expansion through 2035 and beyond